WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported): March 14, 2003


                         COMMISSION FILE NUMBER 1-12584

DELAWARE                           SHEFFIELD PHARMACEUTICALS, INC.           13-3808303
(State of other jurisdiction of    (Exact name of registrant as specified    (I.R.S. Employer
incorporation or organization)     in its charter)                           Identification No.)

          3136 Winton Road South, Suite 201, Rochester, New York       14623
          ------------------------------------------------------     ----------
              (Address of principal executive officers)              (Zip Code)

        Registrant's telephone number, including area code (585) 292-0310


          (Former name or former address, if changed since last report)


(a) Previous independent accountants

(i)           On March 11, 2003, Sheffield Pharmaceuticals, Inc.'s (the
              "Registrant") Audit Committee participated in and approved the
              decision of Ernst & Young LLP to resign as the Registrant's
              independent accountants effective immediately.

(ii)          The reports of Ernst & Young LLP on the financial statements for
              the past two fiscal years ending December 31, 2001 and 2000
              contained no adverse opinion or disclaimer of opinion and were not
              qualified or modified as to uncertainty, audit scope or accounting
              principle, except that, the consolidated financial statements for
              December 31, 2001 included an explanatory paragraph wherein the
              auditor expressed substantial doubt about the Registrant's ability
              to continue as a going concern.

(iii)         In connection with its audits for the two most recent fiscal years
              and through March 11, 2003, there have been no disagreements with
              Ernst & Young LLP on any matter of accounting principles or
              practices, financial statement disclosure, or auditing scope or
              procedure, which disagreements if not resolved to the satisfaction
              of Ernst & Young LLP would have caused them to make reference
              thereto in their report on the financial statements for such

(iv)          The Registrant has requested that Ernst & Young LLP furnish it
              with a letter addressed to the SEC stating whether or not it
              agrees with the above statements. A copy of such letter, dated
              March 13, 2003, is filed as Exhibit 16 to this Form 8-K.

(b) New independent accountants

(i)           The Registrant engaged Rotenberg & Co., LLP, as its new
              independent accountants effective for the audit of the
              Registrant's financial statements for the year ending December 31,
              2002. During the two most recent fiscal years and through March
              13, 2003, the Registrant has not consulted with Rotenberg & Co.,
              LLP regarding either (i) the application of accounting principles
              to a specified transaction, either completed or proposed; or the
              type of audit opinion that might be rendered on the Registrant's
              financial statements, and neither a written report was provided to
              the Registrant nor oral advice was provided that Rotenberg & Co.,
              LLP concluded was an important factor considered by the Registrant
              in reaching a decision as to the accounting, auditing or financial
              reporting issue; or (ii) any matter that was the subject of a
              disagreement, as the term is defined in Item 304(a)(1)(iv) of
              Regulation S-B and the related instructions to Item 304 of
              Regulation S-B.


(c)      Exhibits

Exhibit Number           Description
--------------           -----------

     16                  Letter from Ernst & Young LLP dated March 13, 2003


Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                        SHEFFIELD PHARMACEUTICALS, INC.

Dated:  March 14, 2003                  By: /s/ Thomas M. Fitzgerald
                                           Thomas M. Fitzgerald
                                           President and Chief Executive Officer